Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566329 | 0.77 | AXL (0.40) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL15654873 | 0.77 | AXL (0.48) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL14266837 | 0.77 | AXL (0.48) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL3355756 | 0.73 | SRC (0.49) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL14266846 | 0.73 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL10297741 | 0.73 | PDPK1 (0.39) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL4900637 | 0.72 | AXL (0.43) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL2896258 | 0.72 | AXL (0.43) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL30433865 | 0.71 | AXL (0.41) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL21631702 | 0.71 | ALDH1A1 (0.33) | AXLMKNK1MKNK2DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-07-25 | — | — | US | disclosed |
| EP-4403216-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3822273-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3822273-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2020-12-03 | — | — | US | disclosed |
| EP-3495367-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | AXL 91/4885MKNK1 1638/4885MKNK2 1853/4885 |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | AXL 370/4885MKNK1 652/4885MKNK2 730/4885 |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | AXL 131/4885MKNK1 575/4885MKNK2 642/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | AXL 370/4885MKNK1 652/4885MKNK2 730/4885 |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | AXL 131/4885MKNK1 575/4885MKNK2 642/4885 |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | AXL 131/4885MKNK1 575/4885MKNK2 642/4885 |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | AXL 131/4885MKNK1 575/4885MKNK2 642/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | AXL 424/4885MKNK1 625/4885MKNK2 694/4885 |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | AXL 131/4885MKNK1 575/4885MKNK2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.